ACTHAR Therapy for Central Nervous System Sarcoidosis

Inclusion Criteria: * Patient with sarcoidosis as defined by ATS/ERS/WASOG (American Thoracic Society/European Thoracic Society/World Association for Sarcoidosis and Other Granulomatous Disorders) * Stable baseline immunosuppressive medications * Moderate to severe disease as defined by at least one of the following criteria: * Cranial nerve palsy * Neurologic deficits related to intraparenchymal brain, spinal cord and/or cauda equina involvement * Dural or leptomeningeal involvement of brain and/or spinal cord * Hydrocephalus * Seizures Exclusion Criteria: * Diagnosis of any underlying neurologic disorder that would potentially confound interpretation of the study results * Significant change in corticosteroid dose within the past 4 weeks, or other immunosuppressive medication within the past 6 months * Evidence of current serious infection, or a history of chronic or recurring infections. * Contraindication to high-dose corticosteroids (e.g. uncontrolled blood sugar). * Allergies to pig-derived proteins * Have a history of any opportunistic infection within 6 months prior to screening * History of malignancy.